Forte Biosciences Inc
NASDAQ:FBRX
Forte Biosciences Inc
Total Current Assets
Forte Biosciences Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Forte Biosciences Inc
NASDAQ:FBRX
|
Total Current Assets
$95.4m
|
CAGR 3-Years
29%
|
CAGR 5-Years
35%
|
CAGR 10-Years
7%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Forte Biosciences Inc
Glance View
Forte Biosciences, Inc. is a clinical stage biopharmaceutical company focused on dermatology. The company is headquartered in Torrance, California and currently employs 5 full-time employees. The company went IPO on 2017-04-13. The firm is focused on its lead product candidate, FB-401, which is a topical live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis (AD). FB401 was developed in collaboration with the National Institutes of Health (NIH), and the National Institute of Allergy and Infectious Diseases (NIAID). FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.
See Also
What is Forte Biosciences Inc's Total Current Assets?
Total Current Assets
95.4m
USD
Based on the financial report for Sep 30, 2025, Forte Biosciences Inc's Total Current Assets amounts to 95.4m USD.
What is Forte Biosciences Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
7%
Over the last year, the Total Current Assets growth was 430%. The average annual Total Current Assets growth rates for Forte Biosciences Inc have been 29% over the past three years , 35% over the past five years , and 7% over the past ten years .
